Join our C₂N Diagnostics team at Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, July 31 – August 4
Learn more about C₂N’s PrecivityAD™ test, the first widely accessible blood test for Alzheimer’s disease that is clinically validated and has high diagnostic performance.
Hear it First! Late Breaking Oral Sessions
Multiple oral and poster presentations will offer exciting new insights relating to the PrecivityAD™ blood test and the p-tau MAA. This will include two late-breaking oral presentations both on Sunday, July 31, from 8:00 – 8:45 a.m. PDT (San Diego Convention Center, Ballroom 20A – Hybrid Session #68767). One of these will include Dr. Tim West, C₂N’s VP of R&D, sharing a first look at the diagnostic performance of C₂N’s newest clinical test that combines its plasma amyloid measures with its plasma tau measures.
Session title:
Plasma ratio of phospho- to non-phospho-tau at threonine 217 identifies brain amyloid burden as measured by quantitative amyloid PET in the PARIS sub-study of IDEAS
Session title:
Plasma Aβ42/40 and PET amyloid associations among late-middle-aged African Americans: Preliminary results from the AA-FAIM study.
In addition to these late-breaker presentations, see below for the eleven AAIC posters that will include data on the PrecivityAD™ test across different research applications.
Visit our C₂N Booth – #1001.
When entering the exhibit hall entrance, head to the last row on your right. We encourage you to schedule a meeting with C₂N to explore collaborative opportunities with us.
Keep informed of new publications, updates and recent news about the PrecivityAD™ test by signing up for C₂N’s e-newsletter. Simply add your email address in the form provided on our home page – http://precivityad.com.
Follow us:
Please contact us at 1.877.226.3424 if you have any questions. We look forward to seeing you in San Diego!
PrecivityAD™ Test Data Poster Sessions at AAIC
Sunday, July 31
Sunday, July 31 | Poster
Raindrop animation: Visualizing change in longitudinal biomarker data.
Sunday, July 31 | Poster
Comparison of C₂N Diagnostics’ Aβ40, 42, and 42/40 ratio in Plasma Stored in Micronic and Sarstedt Tubes.
Sunday, July 31 | Virtual Poster
Genetic architecture of plasma Alzheimer disease biomarkers.
Sunday, July 31 | Virtual Poster
Self-report Sleep Duration Associates with Plasma Aβ42/40 Rate of Change in Late Middle-aged, African American Adults.
Sunday, July 31 | Virtual Poster
Genetic architecture of plasma Alzheimer disease biomarkers.
Sunday, July 31 | Virtual Poster
Self-report Sleep Duration Associates with Plasma Aβ42/40 Rate of Change in Late Middle-aged, African American Adults.
Monday, August 1
Monday, August 1 | Poster
Framework for disclosing AD biomarkers results following cognitive assessment within a pragmatic, multi-country implementation evaluation
Monday, August 1 | Poster
Neurophysiologic Correlates of Preclinical Alzheimer's Disease
Tuesday, August 2
Tuesday, August 2 | Poster
Diabetes is related to cognition but not plasma amyloid-β 42/40 in an African American cohort
Tuesday, August 2 | Poster
Trajectories of plasma Aβ42/40 among African Americans: Preliminary results from the African American Fighting Alzheimer’s in Midlife (AA-FIAM) study
Wednesday, August 3
Wednesday, August 3 | Poster
An examination of baseline plasma Aβ42/40 and intra-individual cognitive variability (IICV) associations with longitudinal cognitive change in a Black Cohort: Data from the African Americans Fighting Alzheimer’s in Midlife (AA-FAIM) study.
Wednesday, August 3 | Poster
Worse Performance of Complex Daily Activities is Associated with Plasma Neurofilament Light.
Wednesday, August 3 | Poster
How Naturalistic Driving Compares to Aβ-related CSF and Plasma Biomarkers in the Detection of Amyloid PET Positivity: A Machine Learning Approach.
About C₂N Diagnostics, LLC
C₂N Diagnostics is a specialty diagnostics company with a vision to bring Clarity Through Innovation™. C₂N strives to provide exceptional laboratory services and products in the field of brain health. C₂N’s biomarker services and products are used for: clinical decision making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. For more information visit www.C2N.com.
For the latest news and updates, please visit https://precivityad.com.